Zepbound and Taltz showed improved psoriasis symptoms and weight loss in study

A late-stage trial of 274 patients reported that 27.1% receiving Taltz plus Zepbound achieved complete skin clearance and at least 10% weight loss at 36 weeks, compared with 5.8% on Taltz alone.

Eli Lilly reported results from a late-stage trial testing its weight-loss drug Zepbound given with the psoriasis treatment Taltz in patients who had both psoriasis and obesity. The study enrolled 274 patients and measured outcomes at 36 weeks. Lilly said the combination produced greater improvement in skin symptoms and greater weight loss than Taltz alone. Most participants had psoriasis affecting sensitive areas such as the face, scalp or genitals. Key results: - In the trial of 274 patients, 27.1% who received Taltz plus Zepbound reached complete skin clearance and at least 10% weight loss at 36 weeks, versus 5.8% on Taltz alone, Lilly said. - In a related late-stage analysis, 31.7% of patients receiving the combination met a combined outcome of at least a 50% reduction in psoriatic arthritis activity and at least 10% weight loss, compared with 0.8% for Taltz alone. - Lilly reported that adverse events in the study were generally mild to moderate. - The company noted that in the U.S. about 61% of people with psoriasis also have obesity or are overweight with at least one weight-related co-morbidity. Summary: The trial results reported greater combined improvements in skin symptoms and weight when Zepbound was added to Taltz for patients with psoriasis and obesity. Lilly said detailed results will be published in a peer-reviewed journal and discussed with regulators.